Autologous Dendritic Cell-Tumor Cell Immunotherapy for Metastatic Melanoma

PHASE3TerminatedINTERVENTIONAL
Enrollment

4

Participants

Timeline

Start Date

October 31, 2014

Primary Completion Date

January 31, 2016

Study Completion Date

January 31, 2016

Conditions
Stage IV MelanomaStage III Melanoma
Interventions
BIOLOGICAL

Autologous Dendritic Cell-Tumor Cell Immunotherapy (DC-TC)

Comparison of a cancer treatment containing patient specific irradiated tumor cells mixed with antigen presenting immune cells suspended in an immune system stimulant vs. a cancer treatment containing patient specific immune cells suspended in an immune system stimulant

BIOLOGICAL

Autologous PBMCs in GM-CSF (MC)

Comparison of a cancer treatment containing patient specific irradiated tumor cells mixed with antigen presenting immune cells suspended in an immune system stimulant vs. a cancer treatment containing patient specific immune cells suspended in an immune system stimulant

Trial Locations (18)

18020

Easton

19107

Philadelphia

19111

Philadelphia

21237

Baltimore

37996

Knoxville

40506

Louisville

45219

Cincinnati

46526

Goshen

70072

Marrero

75251

Dallas

80045

Aurora

90033

Los Angeles

90404

Santa Monica

92093

La Jolla

92612

Irvine

92625

Newport Beach

92868

Orange

07601

Hackensack

Sponsors
All Listed Sponsors
lead

Lisata Therapeutics, Inc.

INDUSTRY

NCT01875653 - Autologous Dendritic Cell-Tumor Cell Immunotherapy for Metastatic Melanoma | Biotech Hunter | Biotech Hunter